Given the paucity of gain of function mutations in PIK3CA or loss of function mutations in PTEN observed in medulloblastoma tumors as determined by whole genome sequencing (1–3%), we envision the application of PI-3K inhibitors as adjuncts to existing chemotherapy and radiotherapy regimens in the future treatment of MB once Phase I trials are completed in pediatric oncology. Here, PIK3CA is linked to medulloblastoma.